CRNX at a glance
Crinetics Pharmaceuticals, Inc. (CRNX, SEC CIK 1658247) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on September 1, 2026 and Form 4 insider filings as recently as September 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Crinetics Pharmaceuticals, Inc. (CRNX) reported revenue of $7.7 million (up 640.7% from FY2024) and a net loss of $465.3 million. Diluted EPS was -$4.95.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Crinetics Pharmaceuticals, Inc. (CRNX) shares worth $2.0 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $7.7M
- +640.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $2.0B · +0 vs prior quarter
- Latest 8-K
- Sep 1, 2026
- Item 2.01 · Item 1.02 · Item 3.01 · Item 3.03 · Item 5.03 · Item 5.01 · Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Discovery, development, commercialization of novel small molecule GPCR-targeted therapies for endocrine diseases and endocrine-related tumors
- New product: FDA approved PALSONIFY (paltusotine) in September 2025, first once-daily oral treatment for acromegaly adults inadequately managed by surgery
- Strategic shift: Launching focused U.S. commercial organization for PALSONIFY; expanding globally with EMA marketing authorisation expected H1 2026 and Japan licensing deal
- Key metric: Pipeline includes 10+ disclosed programs; active enrollment in Phase 3 trials for paltusotine in Cushing’s syndrome; positive Phase 2 data on atumelnant with Phase 3 initiated
- Noteworthy fact: PALSONIFY’s approval marks first oral, nonpeptide SST2R agonist for acromegaly, representing a novel therapeutic class and offering improved patient convenience
Risk Factors
- FDA approval risk: PALSONIFY regulatory compliance including U.S. FDA and EMA submissions with risk of delays or denial
- Geopolitical risk: exposure to market disruptions from international conflicts including Russia-Ukraine and Middle East tensions
- Supply chain risk: dependency on third-party manufacturers for clinical and commercial-scale production of PALSONIFY and other candidates
- Competitive risk: potential market disruption if competitor therapies gain faster regulatory approval or wider physician acceptance
- Financial risk: accumulated deficit $1.4B with reliance on $350M equity sales agreement for funding next 12 months
Management Discussion & Analysis
- Revenue $7.7M in 2025 vs $1.0M in 2024, driven by $5.4M product sales from PALSONIFY launch
- Operating margin -681.9% in 2025 vs -326.4% in 2024 (loss from ops $516.8M vs $338.9M on $7.7M vs $1.0M revenue)
- Best segment: Collaboration revenue $2.3M up 119%, worst: operating expenses growth with SG&A up 92% to $191.3M
- Cash, cash equivalents & investments $1.0B at end 2025 down 24%, raised $380M net in Jan 2026 equity offering, no dividends or buybacks
- Outlook: Expects increasing product revenue but continued net losses; risks from R&D, commercialization costs, market acceptance, and global macro factors
AI summary of the CRNX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $25.1M, up $24.1M YoY, driven by PALSONIFY product revenue of $24.0M
- Net loss $120.9M vs $115.6M YoY; operating loss $132.5M vs $129.1M
- Atumelnant R&D $24.8M, up $13.6M YoY; paltusotine R&D $13.7M, down $0.8M
- Cash, equivalents and investments $1.21B vs $1.03B at December 31, 2025; operating cash use $218.9M
- Management expects resources sufficient for at least twelve months; Merger expected to close in third quarter 2026
Risk Factors
- Pending Vertex merger, triggered by July 6, 2026 Merger Agreement, represents the quarter’s newly added risk
- Regulatory closing risk, including HSR Act waiting-period expiration and foreign clearances, could delay completion beyond third quarter 2026
- Merger termination could require approximately $350.5 million payment to Vertex
- Merger restrictions may prevent pursuing competing proposals or attractive business opportunities
- Employee retention risk from uncertainty over post-merger roles could impair execution during the transaction period
AI summary of the CRNX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.01: Completion of Acquisition or Disposition of Assets
- Item 2.01 references the Introductory Note for acquisition or disposition details
- Investors should review the Introductory Note to identify the transaction, consideration, assets, and expected financial impact
Item 1.02: Termination of a Material Definitive Agreement
- Merger completion triggered termination of Crinetics’ employee stock purchase plan
- Equity incentive plans from 2015, 2018, and 2021 terminated at the merger effective time
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- CRNX common stock trading suspended before market open on merger closing date
- Nasdaq delisting and SEC Form 25 deregistration requested following merger completion
Item 3.03: Material Modification to Rights of Security Holders
- Merger converted each outstanding Company common share into the right to receive merger consideration
- Former stockholders lost voting and other equity-holder rights at the merger’s effective time
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Certificate of incorporation and bylaws fully amended and restated effective at merger closing
- Changes implemented under the Merger Agreement, signaling completed transaction mechanics
Item 5.01: Changes in Control of Registrant
- Merger completed, transferring control of Crinetics to Parent
- Crinetics became Parent’s wholly owned subsidiary, eliminating standalone public-company ownership
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Merger completion removed all seven incumbent directors from CRNX’s board and committees
- Resignations unrelated to disagreements over operations, policies, or practices
Item 5.07: Submission of Matters to a Vote of Security Holders
- Merger with Vertex approved: 79,240,098 votes for versus 13,618 against, satisfying the final outstanding closing condition
- 74.71% shareholder participation, with 79,264,631 of 106,095,205 shares represented
Item 8.01: Other Events
- Merger shareholder vote remains scheduled for August 28, 2026; board continues unanimous recommendation for Vertex’s $85-per-share offer
- Litigation and demand letters allege misleading merger disclosures; supplemental proxy disclosures aim to reduce injunction risk and transaction delays
AI summaries of CRNX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CRNX
Don't miss the next CRNX filing
- Alerts as it files. A push when CRNX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CRNX, by share count.
- Ask anything. An AI agent that reads every CRNX filing and answers with sources.
CRNX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bedrosian Camille L | D | Sep 1, 2026 | 16,300 | $85.00 |
| Vivaldi Coelho Rogerio | D | Sep 1, 2026 | 9,730 | $49.13 |
| Vivaldi Coelho Rogerio | D | Sep 1, 2026 | 17,500 | $64.68 |
| Vivaldi Coelho Rogerio | D | Sep 1, 2026 | 8,750 | $66.71 |
| Vivaldi Coelho Rogerio | D | Sep 1, 2026 | 12,500 | $40.29 |
| Vivaldi Coelho Rogerio | D | Sep 1, 2026 | 10,350 | $52.67 |
| Vivaldi Coelho Rogerio | D | Sep 1, 2026 | 13,300 | $85.00 |
| Vivaldi Coelho Rogerio | D | Sep 1, 2026 | 5,925 | $85.00 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.0M | $7.7M |
| Operating Income | - | -$338.9M | -$516.8M |
| Net Income | -$214.5M | -$298.4M | -$465.3M |
| Op. Margin | - | -32613.5% | -6714.8% |
| Net Margin | - | -28720.7% | -6046.2% |
| Balance Sheet | |||
| Total Assets | - | $1.4B | $1.1B |
| Equity | $539.1M | $1.3B | $992.1M |
| ROE | -39.8% | -22.5% | -46.9% |
| Per Share | |||
| EPS | $-3.69 | $-3.69 | $-4.95 |
| Cash Flow | |||
| Operating CF | - | -$226.0M | -$377.9M |
| CapEx | $4.7M | $3.8M | $5.8M |
Source: XBRL data in Crinetics Pharmaceuticals, Inc. (CRNX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CRNX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $1.98B |
| Q1 2026 | 29 | $1.76B |
| Q4 2025 | 25 | $2.11B |
| Q3 2025 | 24 | $1.95B |
| Q2 2025 | 24 | $1.32B |
| Q1 2025 | 20 | $1.05B |
| Q4 2024 | 16 | $1.28B |
| Q3 2024 | 16 | $344.0M |
- BlackRock+1.28M (+15%)
- T. Rowe Price Group+857.2K (+16%)
- Bank of America Corp+616.9K (+86%)
- Goldman Sachs Group+476.8K (+76%)
- Morgan Stanley+418.8K (+46%)
- Ameriprise Financial−301.1K (-38%)
- Citadel Advisors LLC−179.6K (-56%)
- Invesco Ltd−17.0K (-13%)
- Raymond James Financial−1.6K (-3%)
- U.S. Bancorp−94 (-1%)
- Allstate+12.4K
- Millennium Management−62.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 183 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CRNX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| 8-K | Aug 28, 2026 | - | Analysis | - |
| 4 | Aug 24, 2026 | - | - | - |
| 8-K | Aug 19, 2026 | - | Analysis | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 10, 2026 | - | Analysis | - |
| 4 | Jul 7, 2026 | - | - | - |
| 8-K | Jul 6, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CRNX SEC filings: frequently asked questions
Which institutions hold CRNX stock?
As of June 30, 2026, the largest Crinetics Pharmaceuticals, Inc. (CRNX) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($592.7 million), BlackRock ($365.2 million), T. Rowe Price Group ($232.5 million), Vanguard Portfolio Management LLC ($180.8 million), Vanguard Capital Management LLC ($177.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CRNX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Crinetics Pharmaceuticals, Inc. (CRNX) reported revenue of $7.7 million (up 640.7% from FY2024) and a net loss of $465.3 million. Diluted EPS was -$4.95. The figures come from the XBRL data in the 10-K.
What are the main risks in CRNX's latest 10-K?
In the 10-K filed February 26, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) flagged: FDA approval risk: PALSONIFY regulatory compliance including U.S. FDA and EMA submissions with risk of delays or denial. Geopolitical risk: exposure to market disruptions from international conflicts including Russia-Ukraine and Middle East tensions. (AI summary of the Risk Factors section.)
What did CRNX report in its latest 8-K?
Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K on September 1, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 1.02 (Termination of a Material Definitive Agreement), Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 5.01 (Changes in Control of Registrant) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Item 2.01 references the Introductory Note for acquisition or disposition details.
What are the latest CRNX SEC filings?
Crinetics Pharmaceuticals, Inc. (CRNX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on September 1, 2026 and a Form 4 insider filing on September 1, 2026.
What is CRNX's SEC CIK number?
Crinetics Pharmaceuticals, Inc. (CRNX)'s SEC Central Index Key (CIK) is 1658247. EDGAR lists every CRNX filing under that number.
Ask anything about CRNX
The research agent reads CRNX's filings, financials, insider trades and 13F holders, then answers with sources.